NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.
Keith Flaherty
Consultant or Advisory Role - Novartis
Petr Arenberger
Research Funding - Novartis
Paolo Antonio Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche/Genentech; Ventana
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Ventana
Jan Willem De Groot
No relevant relationships to disclose
Sigrun Hallmeyer
No relevant relationships to disclose
Georgina V. Long
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Honoraria - GlaxoSmithKline; Roche
Michal Lotem
No relevant relationships to disclose
Maria Marples
Other Remuneration - Novartis
Dirk Schadendorf
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Merck
Alexander Starodub
No relevant relationships to disclose
Matthew Hiram Taylor
No relevant relationships to disclose
Pascal Wolter
No relevant relationships to disclose
Naoya Yamazaki
No relevant relationships to disclose
Ernesto Wasserman
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
James Ford
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marine Weill
Employment or Leadership Position - Novartis
Reinhard Dummer
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; Merck; Novartis; Roche
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; Merck; Novartis; Roche